Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Managed Health Care0.84%-0.75 ppPharmaceuticals3.52%-0.71 ppBiotechnology1.80%-0.33 ppHealth Care Equipment2.20%-0.32 ppLife Sciences Tools & Services1.00%-0.24 ppHealth Care Distributors0.43%+0.09 ppHealth Care Services0.42%-0.07 ppHealth Care Supplies0.09%-0.05 ppHealth Care Facilities0.21%-0.01 ppHealth Care Technology0.02%-0.01 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
1.80%
Industry change · 12M
-0.33 pp
Biotechnology · contribution
-0.332 pp
Company participation
50%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Oct 2025 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| AbbVie → ABBV | United States | $385.2bn | 0.755% | +0.050 pp | -0.092 pp | +10.7% | Yes |
| Amgen → AMGN | United States | $160.7bn | 0.315% | -0.020 pp | -0.090 pp | -3.7% | No |
| Vertex Pharmaceuticals → VRTX | United States | $109.1bn | 0.214% | -0.034 pp | -0.075 pp | -10.6% | No |
| Regeneron Pharmaceuticals → REGN | United States | $61.2bn | 0.120% | +0.012 pp | -0.065 pp | -21.9% | Yes |
| Gilead Sciences → GILD | United States | $148.6bn | 0.291% | -0.003 pp | +0.031 pp | +38.9% | No |
| Moderna → MRNA | United States | $10.6bn | 0.021% | -0.003 pp | -0.028 pp | -50.0% | No |
| Biogen → BIIB | United States | $22.6bn | 0.044% | +0.005 pp | -0.015 pp | -11.3% | Yes |
| Incyte → INCY | United States | $18.4bn | 0.036% | +0.005 pp | +0.002 pp | +26.1% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.